IP Library › Assignment 033766/0117
Patent Assignment
Reel/Frame 033766/0117

Assignment of Assignor's Interest

Recorded: 2014-09-18 Pages: 3
Assignor
Assignee
SHIRE HUMAN GENETIC THERAPIES, INC.
300 SHIRE WAY, LEXINGTON, MASSACHUSETTS, 02421
Covered Properties (3)
Inhibition of Telopeptide Lysyl Hydroxylase Activity or Production as Anti-Fibrotic Therapy
Patent: 6,733,988 →
Application: 09/450,209 →
Modification of Collagenous Materials and Medical Treatment, Diagnosis and Monitoring of Fibrotic Conditions
Patent: 7,045,600 →
Application: 10/184,372 →
Publication: US 2003/0219852
Method for Preparing Modified Collagen Outside a Host Cell
Patent: 7,932,053 →
Application: 11/547,822 →
Publication: US 2008/0086782
Related Assignments (6)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Feb 24, 2000
From: TE KOPPELE, JOHANNES MARIA; BANK, RUUD ANTONIUS
To: NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO
Reel/Frame 010645/0921 →
Assignment of Assignor's Interest Oct 15, 2002
From: BANK, RUDOLF ANTONIUS; VAN DER SLOT, ANNEMARIE JOZEFIEN; KOPPELE, JOHANNES MARIA TE
To: NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUUR- WETENSCHAPPELIJK ONDERZOEK TNO
Reel/Frame 013383/0775 →
Assignment of Assignor's Interest Mar 23, 2007
From: BANK, RUDOLF ANTONIUS; ZUURMOND, ANNE-MARIE; JORE, JOHANNES PETRUS MARIA; VAN DEN HONDEL, CORNELIS ANTONIUS MARIA JACOBUS JOHANNES
To: NEDERLANDSE ORGANISATIE VOOR TOEGEPASTNATUURWETENSCHAPPELIJK ONDERZOEK TNO
Reel/Frame 019060/0070 →
Assignment of Assignor's Interest Aug 30, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.; LOTUS TISSUE REPAIR, INC.
To: PHOENIX TISSUE REPAIR, INC.
Reel/Frame 043447/0805 →
Security Interest Nov 17, 2021
From: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058144/0302 →
Release of Security Interest Jan 18, 2024
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: BRIDGEBIO PHARMA, INC.; ORIGIN BIOSCIENCES, INC.; EIDOS THERAPEUTICS, INC.; QED THERAPEUTICS, INC.
Reel/Frame 066167/0462 →